Raymond James & Associates Omeros Corp Call Options Transaction History

Raymond James & Associates

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 08, 2023	BUY	$1.75 - $3.96 $60,550 - $137,016	34,600 New	34,600 $78,000
Q2 2022 Aug 12, 2022	SELL	$1.92 - $6.28 $8,832 - $28,888	-4,600 Reduced 9.77%	42,500 $9,000
Q1 2022 May 11, 2022	SELL	$5.07 - $7.2 $32,955 - $46,800	-6,500 Reduced 12.13%	47,100 $11,000
Q3 2021 Nov 02, 2021	BUY	$13.4 - $16.3 $40,200 - $48,900	3,000 Added 5.93%	53,600 $34,000
Q1 2021 May 14, 2021	BUY	$14.52 - $23.53 $348,480 - $564,720	24,000 Added 90.23%	50,600 $152,000
Q3 2020 Nov 04, 2020	SELL	$9.57 - $21.32 $18,183 - $40,508	-1,900 Reduced 6.67%	26,600 $13,000
Q2 2020 Jul 28, 2020	SELL	$12.21 - $16.99 $877,899 - $1.22 Million	-71,900 Reduced 71.61%	28,500 $78,000
Q1 2020 Apr 21, 2020	BUY	$9.03 - $19.72 $442,469 - $966,280	49,000 Added 95.33%	100,400 $52,000
Q3 2019 Nov 07, 2019	BUY	$14.55 - $20.56 $426,315 - $602,408	29,300 Added 132.58%	51,400 $31,000
Q1 2019 May 06, 2019	SELL	$11.65 - $17.72 $288,920 - $439,456	-24,800 Reduced 52.88%	22,100 $10,000
Q3 2018 Nov 14, 2018	BUY	$17.73 - $26.69 $312,048 - $469,744	17,600 Added 60.07%	46,900 $147,000
Q2 2018 Aug 14, 2018	BUY	$10.79 - $24.44 $195,298 - $442,364	18,100 Added 161.61%	29,300 $35,000
Q1 2018 May 14, 2018	SELL	$9.0 - $20.16 $16,200 - $36,288	-1,800 Reduced 13.85%	11,200 $7,000
Q3 2017 Nov 13, 2017	SELL	$19.76 - $24.9 $638,248 - $804,270	-32,300 Reduced 71.3%	13,000 $6,000
Q2 2017 Aug 14, 2017	BUY	N/A	45,300	45,300 $103,000

121

25.6M

228K

630K

Ticker OMER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,730,000
Market Cap $555M
Description
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.